Quantum computers aim to deploy the unique properties of quantum physics to solve problems that are beyond the reach of conventional computers. As this technology matures from experimental systems into practical tools, it promises to unlock faster progress in fields that directly improve lives, including ultra secure communications, powerful new computing architectures, cutting edge sensors and drug discovery.
The recently announced creation of the IonQ Quantum Innovation Centre at University of Cambridge will see the installation of the most powerful quantum computer in the UK, based on IonQ’s latest 256-qubit quantum computing system. As the first commercial-scale quantum computer at a UK university the facility promises to accelerate the delivery of the UK’s National Quantum Strategy. This project, described as “a true partnership” by Professor Mete Atatüre, Head of the Cavendish Laboratory, will bring together cross-disciplinary research across different institutions and industrial partners.
Using qubits rather than classical bits, which can exist in multiple states at once, quantum computers have the potential to explore many possible solutions simultaneously and tackle problems that are intractable to current methods. In the life sciences field, this opens up powerful new possibilities: quantum computers may be able to more accurately simulate molecular behaviour and protein interactions, helping researchers identify promising drug candidates faster and reduce reliance on costly laboratory experiments. Quantum techniques can also complement AI by improving optimisation, analysing complex genomic datasets, and generating high quality synthetic data where real world data is scarce, such as in rare disease research. While quantum technology is still at an early stage, governments, industry and academia are already exploring these applications, recognising quantum computing as a potential step change for drug discovery, diagnostics and personalised medicine.
Life sciences researchers in the UK are already moving beyond theory and engaging with quantum technologies through national infrastructure and applied research programmes. At the National Quantum Computing Centre (NQCC), pharma and biotech organisations are collaborating with academics and technology providers to explore early quantum computing use cases for drug discovery, such as molecular simulation and complex optimisation, using openly accessible quantum platforms designed for industry experimentation. Closer to patient care, the UK Quantum Biomedical Sensing Research Hub (Q-BIOMED) is working with biotech companies and NHS partners to develop quantum enabled diagnostics, including ultra sensitive blood tests and faster imaging for earlier disease detection, with a clear focus on real world healthcare impact.
As this potentially very exciting technology moves from concept to application, we are tracking the evolving legal issues that emerge. We consider below several areas of legal risk that will need to be addressed at the technology evolves and becomes more embedded in life sciences applications.
Intellectual property and ownership
Quantum computing raises complex IP questions, particularly where algorithms, workflows and outputs are developed collaboratively between partners. Determining ownership of quantum derived results, improvements to pre existing models, and rights in jointly developed IP requires careful allocation in collaboration and access agreements. Traditional distinctions between background IP, foreground IP and derived data may not map neatly onto quantum use cases, especially where outputs are probabilistic or model driven.
As with AI-enabled innovation, the IP mix will be different from what we have seen in traditional drug discovery. We can expect to see reliance on a combination of know-how (including trade secrets) and patents, where these are available. In a multi-participant project, IP ownership is likely to sit with different participants and will need to be allocated and licensed with care. As with the telecommunications sector, interoperability standards may be needed to support effective deployment of a network of interconnected technological advances.
Privacy and data protection
Many life sciences use cases will involve sensitive datasets, including clinical and genomic data. Ensuring data protection compliance, with data minimisation and appropriate safeguards remains essential, particularly where research involves cross border data access. Cyber-security concerns are also currently being cited around some quantum technologies.
Regulatory uncertainty and horizon scanning
Quantum computing currently operates in a regulatory grey area, with no sector specific frameworks governing its development or use. However, where there is an intersection with regulated activities, such as drug discovery, AI enabled decision making and clinical trials, existing regulatory regimes will be engaged. More specific regulatory frameworks may be developed as the technology and associated risk profile evolves. Life sciences users will need to engage in proactive horizon scanning, anticipating how emerging quantum capabilities may be captured by future legislation, standards or guidance.
As with AI, the ‘black box’ nature of technology means that predictability and reproducibility are low compared with existing technologies. Effective regulation of a product or system is difficult where its operation is unpredictable; this presents a particular challenge.
Export controls and national security
Quantum technologies are increasingly viewed as strategically sensitive, engaging export controls, investment screening and national security regimes. International collaborations, cross border access to quantum systems or the transfer of quantum related know how may trigger additional legal scrutiny. Managing these risks requires early assessment and alignment with national quantum strategies.
Competition law and antitrust risk
The collaborative nature of quantum computing initiatives in life sciences, is currently essential to progress in this emerging field. This can, however, raise antitrust considerations, particularly where sensitive information is shared, joint priorities are set, or industry standards begin to emerge. Careful structuring of collaborations will be needed to ensure compliance with competition law, including clear limits on information exchange, robust governance arrangements, and distinctions between exploratory, pre competitive research and downstream commercial activity.
Ethics, governance and accountability
More broadly, quantum computing raises questions of governance, transparency and accountability, particularly where outputs inform high impact decisions in healthcare or research prioritisation. Legal teams are working alongside technologists and ethicists to help shape responsible use frameworks, ensure explainability where possible, and build public trust as the technology matures.
In conclusion
As we see new quantum computing facilities being established and put to use, the prospects for this technology to address some of the most intractable life sciences problems are bright. As these applications unfold, developers and users will need to keep track of and address the relevant legal and regulatory frameworks to understand and manage legal and regulatory risks.
Learn more about our technology and life sciences work.
Our content explained
Every piece of content we create is correct on the date it’s published but please don’t rely on it as legal advice. If you’d like to speak to us about your own legal requirements, please contact one of our expert lawyers.